C-reactive protein stimulates RAGE expression in human coronary artery endothelial cells in vitro via ROS generation and ERK/NF-κB activation

Acta Pharmacologica Sinica

Volumn 36, Issue 4, 2015, Pages 440-447

  Zhong, Yun ^a   Cheng, Chuan Fang ^a   Luo, Yi Zhi ^a   Tian, Chao Wei ^a   Yang, Hui ^a   Liu, Ben Rong ^a   Chen, Min Sheng ^a   Chen, Yan Fang ^a,b   Liu, Shi Ming ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

advanced glycosylation end products; atherosclerosis; C reactive protein; endothelial cells; extracellular signal regulated MAP kinases; NF kappa B; p38 mitogen activated protein kinases; reactive oxygen species

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; IMMUNOGLOBULIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; C-REACTIVE PROTEIN; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84926329153     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.163     Document Type: Article

References (31)

1. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-38.
2. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31: 2087-91.
3. Grad E, Danenberg HD. C-reactive protein and atherothrombosis: Cause or effect? Blood Rev 2013; 27: 23-9.
4. Sundgren NC, Zhu W, Yuhanna IS, Chambliss KL, Ahmed M, Tanigaki K, et al. Coupling of Fcaγ receptor I to Fcaγ receptor IIb by src kinase mediates c-reactive protein impairment of endothelial function. Circ Res 2011; 109: 1132-40.
5. Raaz-Schrauder D, Ekici AB, Klinghammer L, Stumpf C, Achenbach S, Herrmann M, et al. The proinflammatory effect of c-reactive protein on human endothelial cells depends on the Fcã IIa genotype. Thromb Res 2014; 133: 426-32.
6. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
7. Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: A review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012; 20: 77-83.
8. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010; 31: 2741-8.
9. Zhang Z, Yang Y, Hill MA, Wu J. Does c-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets? Front Physiol 2012; 3: 433.
10. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: Evidence that c-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-21.
11. Huang X, Zhang J, Liu J, Sun L, Zhao H, Lu Y, et al. C-reactive protein promotes adhesion of monocytes to endothelial cells via nadph oxidase- mediated oxidative stress. J Cell Biochem 2012; 113: 857-67.
12. Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, et al. Crp regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 2009; 583: 2811-8.
13. Mahajan N, Dhawan V. Receptor for advanced glycation end products (rage) in vascular and inflammatory diseases. Int J Cardiol 2013; 168: 1788-94.
14. Morris-Rosenfeld S, Blessing E, Preusch MR, Albrecht C, Bierhaus A, Andrassy M, et al. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. Eur J Clin Investig 2011; 41: 1164-71.
15. Watson AM, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit- Dahm KA, et al. Quinapril treatment abolishes diabetes-associated atherosclerosis in rage/apolipoprotein E double knockout mice. Atherosclerosis 2014; 235: 444-8.
16. Mahajan N, Bahl A, Dhawan V. C-reactive protein (crp) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin. Int J Cardiol 2010; 142: 273-8.
17. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006; 48: 504-11.
18. Wynants M, Vengethasamy L, Ronisz A, Meyns B, Delcroix M, Quarck R. Nf-kappab pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2013; 305: L934-42.
19. Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: Further evidence of endothelial dysfunction. Clin Chem 2011; 57: 1757-61.
20. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. Rage biology, atherosclerosis and diabetes. Clin Sci (Lond) 2011; 121: 43-55.
21. Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006; 26: 2476-82.
22. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent no-mediated dilation in coronary arterioles by activating p38 kinase and nad(p)h oxidase. Arterioscler Thromb Vasc Biol 2005; 25: 995-1001.
23. Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, et al . Crp enhances soluble lox-1 release from macrophages by activating TNFalpha converting enzyme. J Lipid Res 2011; 52: 923-33.
24. Bello G, Cailotto F, Hanriot D, Kolopp-Sarda MN, Latger-Cannard V, Hess K, et al. C-reactive protein (crp) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis 2008; 200: 286-93.
25. Cui C, Shi Q, Zhang X, Liu X, Bai Y, Li J, et al. Crp promotes MMP-10 expression via c-Raf/MEK/ERK and JAK1/ERK pathways in cardiomyocytes. Cell Signal 2012; 24: 810-8.
26. Pamukcu B, Lip GY, Shantsila E. The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011; 128: 117-23.
27. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
28. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. Microrna-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 2012; 122: 1973-90.
29. Liang YJ, Shyu KG, Wang BW, Lai LP. C-reactive protein activates the nuclear factor-kappab pathway and induces vascular cell adhesion molecule-1 expression through cd32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 2006; 40: 412-20.
30. Scirica BM, Morrow DA. Is c-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113: 2128-34.
31. Vaishnav D, Jambal P, Reusch JE, Pugazhenthi S. Sp600125, an inhibitor of c-jun n-terminal kinase, activates CREB by a p38 MAPKmediated pathway. Biochem Biophys Res Commun 2003; 307: 855-60.